Use of btk inhibitor and single dose drug

Through the use of highly selective BTK kinase irreversible inhibitor compound (I), the efficiency and safety of existing BTK inhibitors in the treatment and prevention of immune system diseases have been solved, and effective inhibition of BTK kinase and immune system have been achieved. Effective treatment of the disease improves the compliance and safety of patients.

WO2024235163A1PCT designated stage expired Publication Date: 2024-11-21HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092670
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing BTK inhibitors have efficiency and safety issues in the treatment and prevention of immune system diseases, especially with room for improvement in high selectivity and tolerance.

Method used

Provided a highly selective irreversible inhibitor of BTK kinase, Compound (I) or stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for the preparation of single doses of drugs for treatment It also prevents immune system diseases, and has the advantages of high enzyme activity, good water solubility, low plasma protein binding rate, high oral bioavailability and long oral half-life.

Benefits of technology

Compound (I) significantly improves the inhibitory activity of BTK kinase, effectively treats and prevents immune system diseases, including rheumatoid arthritis, urticaria and skin inflammation, and has good pharmacokinetic and pharmacokinetic properties. Improves patient compliance and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092670_21112024_PF_FP_ABST
    Figure CN2024092670_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A use of a compound represented by formula (I) or a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt of the compound represented by formula (I) in the preparation of a drug, wherein the drug is used for treating and / or preventing immune system diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Uses and single-dose medications for BTK inhibitors

[0001] Priority information

[0002] This application claims priority and benefits of patent application 202310549229.X filed with the State Intellectual Property Office of China on May 12, 2023, and incorporates the entire text of it herein by reference. Technical Field

[0003] The present invention belongs to the field of biopharmaceutical technology. Specifically, the present invention relates to the use of a BTK inhibitor and a single-dose medicine. More specifically, the present invention relates to the use of a BTK inhibitor in the preparation of a medicine for treating and / or preventing immune system diseases and a single-dose medicine. Background Art

[0004] Bruton's Tyrosine Kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases, is a key signaling enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells. BTK plays a crucial role in the B cell signaling pathway, linking cell surface B-cell receptor (BCR) stimulation to downstream intracellular responses. In certain malignancies, BTK is overexpressed in B cells and is associated with increased tumor cell proliferation and survival. Inhibiting BTK affects B cell signaling pathways, preventing B cell activation and inhibiting the growth of malignant B cells. Therefore, inhibiting BTK activity can be used to treat cancer, as well as B cell lymphomas, leukemias, and other hematological malignancies. Numerous clinical trials have demonstrated the efficacy of BTK inhibitors in cancer. The BTK inhibitor ibrutinib (PCI-32765) has been approved by the US Food and Drug Administration for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

[0005] The present invention aims to provide a use of a BTK inhibitor in the preparation of a medicament for treating and / or preventing immune system diseases and a single-dose medicament.

[0006] Summary of the Invention

[0007] The present invention aims to solve, at least to some extent, one of the technical problems existing in the prior art. To this end, the present invention provides a use of a BTK inhibitor in the preparation of a medicament for treating and / or preventing immune system diseases.

[0008] In one aspect of the present invention, the present invention provides a use of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) in the preparation of a medicament for treating and / or preventing immune system diseases;

[0009] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by the above formula (I) serve as highly selective irreversible inhibitors of BTK kinase, which can effectively treat and / or prevent immune system diseases.

[0010] In another aspect of the present invention, the present invention provides a use of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) in treating and / or preventing immune system diseases;

[0011] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by the above formula (I) serve as highly selective irreversible inhibitors of BTK kinase, which can effectively treat and / or prevent immune system diseases.

[0012] In another aspect of the present invention, the present invention provides a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) for use in treating and / or preventing immune system diseases;

[0013] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by the above formula (I) serve as highly selective irreversible inhibitors of BTK kinase, which can effectively treat and / or prevent immune system diseases.

[0014] According to an embodiment of the present invention, the above three aspects of use may further include at least one of the following technical features:

[0015] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0016] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0017] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 5 to 800 mg.

[0018] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 800 mg.

[0019] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 20 to 800 mg.

[0020] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 25 to 800 mg.

[0021] In another aspect of the present invention, a single-dose drug is provided, comprising about 1 to 800 mg of a compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound of formula (I) as an active ingredient.

[0022] According to an embodiment of the present invention, the single-dose medicament can effectively treat and / or prevent immune system diseases.

[0023] In another aspect of the present invention, a single-dose medicament is provided for treating and / or preventing immune system diseases, comprising about 1 to 800 mg of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) as an active ingredient.

[0024] According to an embodiment of the present invention, the single-dose medicine described in the above two aspects may further include at least one of the following technical features:

[0025] :

[0026] According to an embodiment of the present invention, the single-dose medicine contains about 5 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0027] According to an embodiment of the present invention, the single-dose medicine contains about 10 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0028] According to an embodiment of the present invention, the single-dose medicine contains about 20 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0029] According to an embodiment of the present invention, the single-dose medicine contains about 25 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0030] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or skin allergy disease.

[0031] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0032] According to an embodiment of the present invention, the urticaria includes chronic spontaneous urticaria.

[0033] In another aspect of the present invention, a method for treating and / or preventing immune system diseases is provided, comprising: administering to a subject a pharmaceutically acceptable dose of a compound of formula (I) or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, or a single dose of the aforementioned compound of formula (I);

[0034] In some optional embodiments of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0035] In some optional embodiments of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0036] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of the embodiments with reference to the accompanying drawings, in which:

[0038] FIG1 is a graph showing the C of compound (I) capsules after a single administration in each dosage group in the clinical trial of Example 2 of the present invention. max Correlation with the dose of compound (I);

[0039] FIG2 is the AUC of compound (I) capsules after single administration in each dose group (10-100 mg) in the clinical trial of Example 2 of the present invention 0-tCorrelation with the dose of compound (I);

[0040] FIG3 shows the AUC of compound (I) capsules after a single administration in each dose group (200-800 mg) in the clinical trial of Example 2 of the present invention. 0- t Correlation with the dose of compound (I);

[0041] FIG4 shows the change in BTK target site occupancy over time for each dose group of Compound (I) capsule in the clinical trial of Example 2 of the present invention;

[0042] FIG5 shows all subjects C in the clinical trial of Example 2 of the present invention. max Curve fitting with BTK target occupancy max;

[0043] FIG6 shows the AUC of all subjects in the clinical trial of Example 2 of the present invention. last Curve fitting with BTK target occupancy max. DETAILED DESCRIPTION

[0044] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0045] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.

[0046] The endpoints and any values ​​of the scopes disclosed herein are not limited to the precise scope or value, and these scopes or values ​​should be understood to include values ​​close to these scopes or values. For numerical ranges, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between separate point values, one or more new numerical ranges can be combined with each other, and these numerical ranges should be considered to be specifically disclosed in this article. Certain ranges are provided herein with numerical values ​​preceded by the term "about." The term "about" is used herein to provide textual support for the precise numerical value preceding it and the numerical value before approaching or approximating the term. In determining whether a numerical value is close to or approximating a specifically stated numerical value, the unstated numerical value that is close to or approximate can be such a numerical value, and in the context in which it is provided, it provides the substantial equivalence of the specifically stated numerical value. The term "about" or "approximately" refers to an acceptable error for a particular value determined by those skilled in the art, which depends in part on how to measure or determine the value. In certain embodiments, the term "about" or "approximately" refers to within 1, 2, 3 or 4 standard deviations. In certain embodiments, the term "about" or "approximately" means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.

[0047] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.

[0048] As used herein, the compounds of the present invention also include isotopically labeled compounds of the present invention, which are identical to those described herein except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Exemplary isotopes that may also be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 16 O. 17 O. 31 P. 32 P. 36 S. 18 F and 37 Cl.

[0049] The term "stereoisomer" refers to isomers resulting from the different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformers. The stereochemical definitions and conventions used herein are generally those of SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.

[0050] As used herein, the term "tautomer" or "tautomeric form" refers to structural isomers with different energies that can be converted into each other through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of the tautomers can be reached. For example, proton tautomers (also known as prototropic tautomers) include interconversions that occur through proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions that occur through the reorganization of some bonding electrons. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.

[0051] As used herein, the term "solvate" refers to an association formed between one or more solvent molecules and a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association formed when the solvent molecule is water.

[0052] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal to be treated therewith.

[0053] As used herein, the term "pharmaceutically acceptable salts" refers to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19.

[0054] As used herein, the term "treatment" refers to any agent used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing a compound described herein to an individual in need.

[0055] The present invention provides a use of a BTK inhibitor in the preparation of a medicament for treating and / or preventing immune system diseases and a single-dose medicament, which are described in detail below.

[0056] use

[0057] In one aspect of the present invention, the present invention provides a use of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) in the preparation of a medicament for treating and / or preventing immune system diseases;

[0058] According to the embodiments of the present invention, the compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) (hereinafter referred to as the compound) is a highly selective irreversible inhibitor of BTK kinase, which can effectively treat and / or prevent immune system diseases. In addition, the above compound has a large drug safety window, has a low onset dose, and has better safety in clinical application, thereby greatly improving patient compliance.

[0059] According to embodiments of the present invention, the above-mentioned compounds have advantages such as high enzymatic activity, good water solubility, low human plasma protein binding rate, high oral bioavailability or long oral half-life. In clinical applications, they have better safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness, thereby greatly improving patient compliance.

[0060] In another aspect of the present invention, the present invention provides a use of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) in treating and / or preventing immune system diseases;

[0061] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) are highly selective irreversible inhibitors of BTK kinase, having the advantages of high enzyme activity, good water solubility, low human plasma protein binding rate, high oral bioavailability or long oral half-life, and can effectively treat and / or prevent immune system diseases.

[0062] In another aspect of the present invention, the present invention provides a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) for use in treating and / or preventing immune system diseases;

[0063] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) are highly selective irreversible inhibitors of BTK kinase, having the advantages of high enzyme activity, good water solubility, low human plasma protein binding rate, high oral bioavailability or long oral half-life, and can effectively treat and / or prevent immune system diseases.

[0064] According to an embodiment of the present invention, the above three aspects of use may further include at least one of the following technical features:

[0065] In some optional embodiments of the present invention, the immune system disease includes autoimmune disease and / or skin allergy disease. The compound according to the embodiment of the present invention has high selectivity for drug efficacy target and significant efficacy in two different animal models.

[0066] In this article, “skin allergic disease” and “skin allergic reaction” are synonymous unless otherwise specified.

[0067] In some optional embodiments of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0068] In some optional embodiments of the present invention, the autoimmune disease includes rheumatoid arthritis and / or urticaria.

[0069] In some optional embodiments of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.

[0070] In some optional embodiments of the present invention, the urticaria comprises chronic spontaneous urticaria.

[0071] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 5 to 800 mg.

[0072] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 800 mg.

[0073] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 20 to 800 mg.

[0074] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 25 to 800 mg.

[0075] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 100 mg.

[0076] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 200 to 800 mg.

[0077] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 1-5 mg, 1-10 mg, 1-25 mg, 1-50 mg, 1-100 mg, 1-200 mg, 1-400 mg, 1-600 mg, 1-800 mg, 5-10 mg, 5-25 mg, 5-50 mg, 5-100 mg, 5-200 mg, 5-400 mg, 5-600 mg, 5-800 mg, 10-25 mg, 10-50 mg, 10-100 mg, 10-200 mg , 10-400mg, 10-600mg, 10-800mg, 25-50mg, 25-100mg, 25-200mg, 25-400mg, 25-600mg, 25-800mg, 50-100mg, 50-200mg, 50-400mg, 50-600mg, 50-800mg, 100-200mg, 100-400mg, 100-600mg, 100-800mg, 200-400mg, 200-600mg, 200-800mg, 400-600mg, 400-800mg or 600-800mg.

[0078] In some optional embodiments of the present invention, the type of the drug is not specifically limited, as long as it comprises a compound shown in formula (I) or a stereoisomer, tautomer, solvate, or a pharmaceutically acceptable salt of a compound shown in formula (I). In some optional embodiments of the present invention, the drug is suitable for oral administration, for example, it may be a solid oral preparation, wherein the solid oral preparation comprises a compound shown in formula (I) or a stereoisomer, tautomer, solvate, or a pharmaceutically acceptable salt of a compound shown in formula (I), and preferably, the compound shown in formula (I) or a stereoisomer, tautomer, solvate, or a pharmaceutically acceptable salt of a compound shown in formula (I) in the solid oral preparation is the only active ingredient. In an optional embodiment of the present invention, the solid oral preparation includes but is not limited to capsules, tablets, dispersible powders, and granules.

[0079] In an optional embodiment of the present invention, the solid oral dosage form may further include excipients, which are well known to those skilled in the art. In an optional embodiment of the present invention, the excipients include, but are not limited to, at least one of a filler, a diluent, a disintegrant, a lubricant, a surfactant, and a binder. In some optional embodiments of the present invention, the filler includes, but is not limited to, at least one of pregelatinized starch, mannitol, microcrystalline cellulose, and lactose. In some optional embodiments of the present invention, the diluent includes, but is not limited to, at least one of calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate. In some optional embodiments of the present invention, the disintegrant includes, but is not limited to, at least one of croscarmellose sodium, sodium starch glycolate, and cross-linked polyvinylpyrrolidone. In some optional embodiments of the present invention, the lubricant includes, but is not limited to, at least one of magnesium stearate, calcium stearate, and talc. In some optional embodiments of the present invention, the binder includes, but is not limited to, at least one of hypromellose, povidone K30, and hydroxypropyl cellulose. In some optional embodiments of the present invention, the surfactant includes, but is not limited to, at least one of sodium lauryl sulfate and Tween 80.

[0080] It should be noted that the efficacy of the drug is mainly determined by the active ingredient (i.e., the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I)).

[0081] In some optional embodiments of the present invention, the solid oral preparation includes but is not limited to capsules, in which the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) are the only active ingredients.

[0082] In some optional embodiments of the present invention, the excipients of the capsule include but are not limited to at least one of a filler, a disintegrant, a lubricant, a surfactant and a binder.

[0083] In some optional embodiments of the present invention, the capsule comprises a compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof, pregelatinized starch, cross-linked sodium carboxymethyl cellulose, and magnesium stearate. Subsequent clinical trials, such as those for efficacy, pharmacokinetic testing, and safety testing, can be conducted using the capsule.

[0084] Single-dose medication

[0085] In another aspect of the present invention, a single-dose drug is provided, comprising about 1 to 800 mg of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) as an active ingredient.

[0086] In some optional embodiments of the present invention, the present invention provides a single-dose drug for treating and / or preventing immune system diseases, comprising about 1 to 800 mg of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) as an active ingredient,

[0087] The compound represented by the above formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by the above formula (I) serve as highly selective irreversible inhibitors of BTK kinase, which can effectively treat and / or prevent immune system diseases.

[0088] As used herein, the term "single dose" refers to a dose for a single use; illustratively, a "single dose of a drug" refers to a dose that can achieve the effect of treating and / or preventing immune system diseases by a single addition of a compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of a compound of formula (I). Preferably, the single dose of the drug contains the compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of a compound of formula (I) as the sole active ingredient.

[0089] In some optional embodiments of the present invention, the single-dose medicine contains about 1 to 800 mg of the compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound of formula (I) as an active ingredient.

[0090] In some optional embodiments of the present invention, the single dose of the drug contains about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg or 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) as an active ingredient, or a range value between any two numbers: for example, 1-5 mg, 1-10 mg, 1-25 mg, 1-50 mg, 1-100 mg, 1-200 mg, 1-400 mg, 1-600 mg, 1-800 mg, 5-10 mg, 5-25 mg, 5-50 mg, 5-100 mg, 5-200 mg, 5-400 mg, 5-600 mg, 5-800mg, 10-25mg, 10-50mg, 10-100mg, 10-200mg, 10-400mg, 10-600mg, 10-800 mg, 25-50mg, 25-100mg, 25-200mg, 25-400mg, 25-600mg, 25-800mg, 50-100mg, 50 -200mg, 50-400mg, 50-600mg, 50-800mg, 100-200mg, 100-400mg, 100-600mg, 100 -800mg, 200-400mg, 200-600mg, 200-800mg, 400-600mg, 400-800mg, 600-800mg.

[0091] According to an embodiment of the present invention, the single-dose medicine contains about 5 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0092] According to an embodiment of the present invention, the single-dose medicine contains about 10 to 800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0093] In some optional embodiments of the present invention, the single-dose drug comprises about 20 to 800 mg of the compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof as an active ingredient. This can further increase the maximum BTK target occupancy rate of the single-dose drug, with the occupancy rate reaching up to 100%.

[0094] In some optional embodiments of the present invention, the single-dose medicine contains about 25 to 800 mg of the compound of formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound of formula (I) as an active ingredient.

[0095] According to an embodiment of the present invention, the single-dose medicine contains about 10-100 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0096] According to an embodiment of the present invention, the single-dose medicine contains about 200-800 mg of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) as an active ingredient.

[0097] In some optional embodiments of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0098] In some optional embodiments of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0099] In some optional embodiments of the present invention, the immune disease includes rheumatoid arthritis and / or skin allergy disease.

[0100] In some optional embodiments of the present invention, the autoimmune disease includes rheumatoid arthritis and / or urticaria.

[0101] In some optional embodiments of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.

[0102] In some optional embodiments of the present invention, the skin allergic diseases include urticaria and eczema.

[0103] In some optional embodiments of the present invention, the urticaria comprises chronic spontaneous urticaria.

[0104] Methods for treating and / or preventing immune system disorders

[0105] In another aspect of the present invention, a method for treating and / or preventing immune system diseases is provided, comprising: administering to a subject a pharmaceutically acceptable dose of a compound of formula (I) or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, or a single dose of the aforementioned compound of formula (I);

[0106] In some optional embodiments of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0107] In some optional embodiments of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0108] In some optional embodiments of the present invention, the autoimmune disease includes rheumatoid arthritis and / or urticaria.

[0109] In some optional embodiments of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.

[0110] In some optional embodiments of the present invention, the urticaria comprises chronic spontaneous urticaria.

[0111] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 5 to 800 mg.

[0112] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 800 mg.

[0113] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 20 to 800 mg.

[0114] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 25 to 800 mg.

[0115] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 100 mg.

[0116] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 200 to 800 mg.

[0117] According to an embodiment of the present invention, the effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 1-5 mg, 1-10 mg, 1-25 mg, 1-50 mg, 1-100 mg, 1-200 mg, 1-400 mg, 1-600 mg, 1-800 mg, 5-10 mg, 5-25 mg, 5-50 mg, 5-100 mg, 5-200 mg, 5-400 mg, 5-600 mg, 5-800 mg, 10-25 mg, 10-50 mg, 10-100 mg, 10-200 mg , 10-400mg, 10-600mg, 10-800mg, 25-50mg, 25-100mg, 25-200mg, 25-400mg, 25-600mg, 25-800mg, 50-100mg, 50-200mg, 50-400mg, 50-600mg, 50-800mg, 100-200mg, 100-400mg, 100-600mg, 100-800mg, 200-400mg, 200-600mg, 200-800mg, 400-600mg, 400-800mg or 600-800mg.

[0118] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.

[0119] The preparation of the compound of formula (I) ((R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one) used in the examples of the present invention is described in Scheme 29 and Example 32 of CN105837576A;

[0120] The CC-292 compound in the examples of the present invention is a commercially available product.

[0121] Example 1: Pharmacological studies of compound (I)

[0122] 1. In vitro efficacy study of compound (I)

[0123] 1.1 Study on the Inhibition of BTK Kinase Activity

[0124] The preparation method of compound (I) in this step is as follows: 1.87 mg of the compound powder represented by formula (I) (purity: 98.7%) is dissolved in 409 μL of 100% DMSO solution to obtain a 10 mM test compound solution, namely compound (I).

[0125] The CC-292 solution in this step was prepared by dissolving 1.80 mg of CC-292 compound powder (98.7% purity) in 425 μL of 100% DMSO solution to obtain a 10 mM test compound solution, which is the CC-292 solution, hereinafter referred to as CC-292.

[0126] Fluorescence conjugate energy transfer (FECT) by Cisbio's homogeneous time-resolved fluorescence ( Method), the inhibition test of the test compound (i.e., compound (I)) and the reference control drug (i.e., CC-292) on BTK kinase activity was investigated. The specific test steps are as follows:

[0127] A. Use Agilent Bravo to take 2.5 μL of the diluted compound (Compound (I) or CC-292), transfer it to the assay plate, and centrifuge at 1000 rpm for 1 minute.

[0128] B. Prepare BTK kinase / peptide solution (2866 μL 1.33X kinase reaction buffer (1330 μL 5X Kinase Reaction Buffer (13.3 μL 1 M MgCl2, 6.65 μL 1 M DTT, 3670 μL ddH2O), 1.53 μL 3.92 μM BTK, 12 μL 500 μM TK Substrate, and 120 μL 2.5 μM SEB) was added to the assay plate. 5 μL of the BTK kinase / peptide mixture was added to each well and centrifuged at 1000 rpm for 1 minute. The plate was incubated at 23°C for 15 minutes.

[0129] C. Prepare ATP solution (3968 μL 1.33X kinase reaction buffer and 32 mL 10 mM ATP). Add 2.5 μL of ATP solution to each well of the assay plate. Centrifuge at 1000 rpm for 1 minute and incubate at 23°C for 90 minutes.

[0130] D. Prepare the detection reagent (20738 μL Detection buffer, 157.5 μL of 16.67 M streptavidin-labeled XL665, and 105 μL of 2.67 M anti-TK phosphorylated peptide substrate antibody were added to the assay plate, 10 μL per well, and centrifuged at 1000 rpm for 1 minute. Incubate at 23°C for 60 minutes, and read the plate on the Envision Multilabel Reader.

[0131] E.IC 50 The results were analyzed using XLFIT5 (205 formula) from IDBS.

[0132] The results showed that compound (I) (IC 50 ≤4nM) has a higher inhibitory activity against BTK kinase than CC-292 (IC 50 about 20 nM) is more preferred.

[0133] 1.2 Study on the antagonism of IgM-induced calcium signaling in RAMOS cells

[0134] In this step, compound (I) was prepared by dissolving 2.63 mg of the compound powder represented by formula (I) (purity: 98.7%) in 575 μL of 100% DMSO solution to obtain a 10 mM test compound solution, namely compound (I).

[0135] The CC-292 solution in this step was prepared by dissolving 2.14 mg of commercially available CC-292 compound powder (98.7% purity) in 505 μL of 100% DMSO solution to obtain a 10 mM test compound solution, which is the CC-292 solution, hereinafter referred to as CC-292.

[0136] Using Life Technologies' Fluo-4D calcium fluorescent dye, the high-throughput CCD imaging plate reader FLIPR was used to measure changes in intracellular calcium signals in real time. The inhibitory effects of compound (I) and CC-292 on IgM-induced calcium signals in RAMOS cells were investigated. The specific experimental steps are as follows:

[0137] A. Ramos cells (ECACC) were cultured in a 384-well plate using cell culture medium (RPMI 1640 medium supplemented with fetal bovine serum to a concentration of 10%) at a density of 5 × 10 6 / mL, 20 μL per well.

[0138] B. Dilute the compound (Compound (I) or CC-292) with DMSO in a 384-well compound plate and transfer to the culture medium, 25 μL per well.

[0139] C. Place the cell plate and compound plate into the FLIPR. Use the FLIPR to aspirate 10 μL of solution from the compound plate and add it to the cell plate. Remove the cell plate and incubate it in a 37°C incubator for 1 hour.

[0140] D. One hour later, 40 μL of Fluo-4D dye (Life Technologies, prepared to 0.5X using 40 ml of HBSS and HEPES buffer) was added to the cell plate and incubated at 37°C for 50 minutes.

[0141] E. Add 10 μL of IgM at 8 times the EC80 concentration and read the plate using FLIPR.

[0142] F. Compound IC 50 The results were analyzed using EXCEL and Prism statistical software.

[0143] The results showed that compound (I) had a partial antagonistic effect on CC-292. 50 55±3.34nM) was generally superior to CC-292 (IC 50 is 170.7±4.03nM).

[0144] 2. In vivo efficacy study of compound (I)

[0145] 2.1 Evaluation of the in vivo efficacy model of collagen-induced arthritis (CIA) in mice

[0146] In this step, the solvent is prepared at a volume ratio of DMSO:40% HP-β-CD:water of 5:15:80 (10 ml of DMSO, 30 ml of 40% HP-β-CD, and 160 ml of MilliQ pure water are mixed and then divided into portions).

[0147] In this step, Compound (I) (or test compound (I)) is prepared by weighing a predetermined amount of the compound of formula (I), adding the calculated volume of DMSO, and vortexing until dissolved. DMSO solution, 40% HP-β-CD, and MilliQ purified water are then added (wherein the volume ratio of DMSO:40% HP-β-CD:water = 5:15:80). This solution is thoroughly mixed and diluted threefold to the dosing concentration, ultimately yielding Compound (I) at the specified dosing concentration.

[0148] In this step, the CC-292 solution was prepared by weighing a predetermined amount of CC-292 compound (98.7% purity), adding the calculated volume of DMSO, and vortexing until dissolved. Then, a 40% HP-β-CD solution in DMSO and MilliQ water (with a volume ratio of DMSO:40% HP-β-CD:water = 5:15:80) were added. This solution was thoroughly mixed and diluted threefold to the desired dosing concentration to obtain the desired CC-292 concentration.

[0149] The collagen-induced mouse arthritis model is a classic animal model used to evaluate the efficacy of drugs for rheumatoid arthritis (RA). Its pathogenesis and symptoms are clearly related to RA. Clinical symptoms of arthritis are induced in mice by injecting collagen emulsion into the tail. The specific steps are as follows:

[0150] DBA / 1 mice were randomly divided into 6 groups, 10 mice per group, excluding a blank control group (5 mice). Mice in the normal group did not require immunization; all other groups were immunized. The day of the first immunization was designated as day 0, and subsequent days were labeled sequentially. DBA / 1 mice were anesthetized with isoflurane and injected subcutaneously with 50 μL of the prepared collagen emulsion (containing 200 μg of CII) into the tail (2-3 cm from the base of the tail). On day 21, the same volume of collagen emulsion was injected into the tail using the same method.

[0151] On day 28, when the average clinical score reached 1 to 2, the mice were re-randomized into four treatment groups (10 mice per group) and a blank vehicle control group (10 mice per group) based on body weight and score. The relevant dosage design of the test compound (I) and the control compound CC-292 was determined based on the results of the previous pilot experiment. The first group was a normal group (not fed any drugs or solvents); the second group was given a blank solvent control (the solvent was 10 mL / kg); the third group was given CC-292 at a dose of 3 mg / kg (the concentration of CC-292 was 0.3 mg / mL and the administration volume was 10 mL / kg); the fourth, fifth and sixth groups were given compound (I) at doses of 1 mg / kg (the concentration of compound (I) was 0.1 mg / mL and the administration volume was 10 mL / kg), 3 mg / kg (the concentration of compound (I) was 0.3 mg / mL and the administration volume was 10 mL / kg) and 10 mg / kg (the concentration of compound (I) was 1 mg / mL and the administration volume was 10 mL / kg). The drug was administered once a day for a total of 14 days. The oral administration volume was 10 mL / kg. After the administration, the clinical score curve of each animal in each group was analyzed, and the area under the curve (AUC) was calculated. The inhibition rate of each drug administration group relative to the blank solvent control was calculated by the average AUC between groups.

[0152] Clinical Observation: From 7 days before immunization to day 21 after immunization, the basic health status and weight changes of DBA / 1 mice were observed daily (recorded twice a week). After day 22, the health status, disease incidence, and weight changes of the mice were observed daily (recorded every two days) until the end of the experiment.

[0153] Clinical Scoring: After boosting immunity, mice were observed daily for disease progression. Once disease onset (clinical signs of arthritis) developed, mice were scored on a scale of 0-4 based on the severity of the lesion (redness, swelling, joint deformity), with a maximum score of 4 for each limb and 16 for each animal. Scoring was performed at least three times weekly.

[0154] Pathology: On day 42, mice were euthanized. Both hind limbs were removed, soaked in 10% formalin, decalcified with formic acid, embedded in paraffin, sectioned, and stained with hematoxylin-eosin (HE). Microscopic photographs were taken and observed. The degree of joint damage was assessed based on four criteria: inflammatory cell infiltration, pannus formation, cartilage damage, and bone resorption, with a score of 0-4.

[0155] The experimental results showed that compared with the normal control group, the average body weight of each immunized group decreased significantly after administration. After day 33, the average body weight of the 1 mg / kg compound (I) treatment group remained essentially unchanged, while the average body weight of the 3 mg / kg and 10 mg / kg compound (I) treatment groups increased. The body weight of the 10 mg / kg group showed significant differences compared to the blank vehicle control group on days 37 and 40, demonstrating a good weight recovery effect.

[0156] The inflammatory inhibition rate was 65.5% in the 1 mg / kg group, 82.4% in the 3 mg / kg group, and 83.9% in the 10 mg / kg group. All three doses showed highly significant differences compared to the blank vehicle control (p<0.001), demonstrating a dose-dependent relationship. The inflammatory inhibition rate was 29.1% in the 3 mg / kg CC-292 group, which showed no significant difference compared to the blank vehicle control.

[0157] Pathological studies revealed only mild inflammation in the foot joint bone tissue at the three dose groups (1, 3, and 10 mg / kg) of Compound (I). Histopathological scores decreased with increasing dose in a dose-dependent manner, and were significantly different from those in the blank vehicle control group. The reference control, CC-292 (3 mg / kg), showed some inflammation and significant bone damage, but the histopathological scores were not significantly different from those in the blank vehicle control group.

[0158] 2.2 Evaluation of the efficacy of PG-PS in rat arthritis model

[0159] In this step, the solvent is prepared by mixing DMSO: 40% HP-β-CD: water in a volume ratio of 5:15:80.

[0160] In this step, Compound (I) (or test compound (I)) is prepared by weighing a predetermined amount of the compound represented by Formula (I), adding the calculated volume of DMSO, and vortexing until dissolved. DMSO solution, 40% HP-β-CD, and MilliQ purified water are then added (wherein the volume ratio of DMSO:40% HP-β-CD:water = 5:15:80). This solution is thoroughly mixed to obtain the desired dosing concentration of Compound (I).

[0161] In this step, the CC-292 solution is prepared by weighing 15 mg of CC-292 compound (98.7% purity), dissolving it in 2.5 mL of DMSO, and mixing it with 7.5 mL of 40% HP-β-CD and 40 mL of deionized water to obtain a final concentration of 3 mg / 10 mL of CC-292. Intraperitoneal injection of PG-PS suspension can effectively induce chronic, erosive, and relapsing symptoms similar to those of human rheumatoid arthritis in rats and is often used in the early development of arthritis drugs to evaluate their in vivo efficacy. The specific steps are as follows:

[0162] On day 0, Lewis rats were randomly divided into 6 groups, with 5 rats in group 1 and 10 rats in each group of groups 2-6. All rats in groups 2-6 were intraperitoneally injected with PG-PS (Lee Laboratories, PG-PS10S, 5.1 mg / ml Rhamnose) to establish the model. The PG-PS injection dose v = 15 μg / g × bw (rat weight, in g) / 5.1 μg / μL.

[0163] On day 1, the model rats (Groups 2-6) were randomly divided into 5 groups, each with 10 rats. Each group was given the corresponding drug or vehicle by gavage once a day until day 29. Group 1 was a normal group, with a dose of 1 mL / kg (test substance as vehicle); Group 2 was given a blank vehicle control, with a dose of 1 mL / kg (test substance as vehicle); Group 3 was given CC-292 at a dose of 3 mg / kg (CC-292 concentration of 0.3 mg / mL, administration volume of 10 mL / kg); Groups 4, 5, and 6 were given Compound (I) at doses of 1 mg / kg (Compound (I) concentration of 0.1 mg / mL, administration volume of 10 mL / kg), 3 mg / kg (Compound (I) concentration of 0.3 mg / mL, administration volume of 10 mL / kg), and 10 mg / kg (Compound (I) concentration of 1 mg / mL, administration volume of 10 mL / kg), respectively. Clinical observation and clinical scoring were performed every day during the administration period. The ankle diameter of each animal after modeling was subtracted from its ankle diameter before modeling to obtain the ankle diameter difference (Delta ankle diameter). The area under the curve (AUC) was calculated by analyzing the ankle diameter difference of each animal in each group. The inhibition rate of each dosing group relative to the blank solvent control was calculated by the average AUC between groups.

[0164] Pathology: On day 30, rats were euthanized. The hind limbs of the rats were stained with toluidine blue to evaluate the severity of joint damage, including inflammatory cell lesions, pannus formation, cartilage damage, bone resorption, and periosteal new bone formation. The severity was scored on a scale of 0-7.

[0165] The experimental results showed that the inhibition rate of the 1 mg / kg compound (I) group was 47.7%, the 3 mg / kg compound (I) group was 64.7%, and the 10 mg / kg compound (I) group was 77.3%. Compared with the blank vehicle control, the 3 mg / kg and 10 mg / kg doses showed extremely significant differences (p < 0.001) and a certain dose-response relationship. The 1 mg / kg compound (I) group also showed a significant difference (p < 0.01). The inhibition rate of the 3 mg / kg CC-292 group was -0.1%. Compared with the blank vehicle control, the 3 mg / kg CC-292 group did not show an inhibitory trend.

[0166] Pathological studies showed that the 3 mg / kg and 10 mg / kg groups of Compound (I) significantly improved joint tissue lesions, with significant differences in scoring (p<0.05). The 1 mg / kg group of Compound (I) showed a trend toward lessening tissue damage, but no significant difference was observed. The 3 mg / kg CC-292 group had more severe tissue lesions, with the average scoring result slightly lower than the blank vehicle control group, but no significant difference was observed.

[0167] 2.3 Efficacy evaluation in passive cutaneous anaphylaxis (PCA) animal model

[0168] Passive skin allergy testing, also known as PCA, is a local allergic reaction induced by antibodies that bind to tissues of the same or different species. The PCA animal model used in this application involves passive sensitization through the binding of IgE to specific receptors on skin mast cells. When challenged with an allergen, local mast cells release allergic mediators, increasing local vascular permeability. This is often used as a drug efficacy model for urticaria and can also demonstrate the anti-allergic effects of drugs during the development of skin inflammation and eczema. The specific steps are as follows:

[0169] In this step, Compound (I) is prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A predetermined amount of the compound of Formula (I) is weighed and dissolved in a calculated volume of DMSO. The mixture is then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL plus deionized water to obtain the desired dosing concentration of Compound (I).

[0170] In this step, prednisone was formulated with 0.5% CMC-Na (sodium carboxymethylcellulose).

[0171] In this step, cetirizine is prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A certain amount of cetirizine is weighed and dissolved in a calculated volume of DMSO. The mixture is then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL plus deionized water to obtain the desired dosing concentration of cetirizine. (All cetirizine compositions in subsequent examples contain the solvent.)

[0172] In this step, LOU-064 is prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A predetermined amount of LOU-064 is weighed and dissolved in the calculated volume of DMSO. The solution is then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL and deionized water to obtain a LOU-064 solution at the desired dosing concentration. The pH of LOU-064 is then adjusted to obtain a clear solution.

[0173] The PCA model in mice was induced by anti-DNP IgE. Specifically, BALB / c mice were divided into 9 groups: normal control group (no medication, injection or feeding of any solvent), model group (no medication, injection or feeding of any solvent), prednisone group (10 mg / kg, The rats were administered QD (once a day) for 3 consecutive days, wherein the concentration of prednisone was 1 mg / mL and the administration volume was 10 mL / kg), cetirizine group (20 mg / kg, QD for 3 consecutive days, wherein the concentration of cetirizine was 2 mg / mL and the administration volume was 10 mL / kg), low- and medium-dose groups of the test substance LOU-064 (15 and 45 mg / kg, BID (twice a day) for 3 consecutive days, wherein the concentration of LOU-064 was 1.5 and 4.5 mg / mL, respectively, and the administration volume was 10 mL / kg), and low-, medium-, and high-dose groups of compound (I) (15, 45 and 90 mg / kg, BID for 3 consecutive days, wherein the concentration of compound (I) was 1.5, 4.5 and 9 mg / mL, respectively, and the administration volume was 10 mL / kg), with 9 rats in each group, administered by gavage, for a total of 4 days. On the 3rd day, administration was injected into 8 groups of left ears of mice (without normal control group) with anti-DNP IgE (Sigma-Aldrich), and the PBS of the left and right ears of the right ear of 8 groups and the normal control group were injected with the same volume, so that it was combined with mast cell. Then anti-DNP IgE was injected after the 24h on the 4th day, with the mixed solution (0.25mL / only of antigen (DNP-HAS, Sigma) and pigment Evan's Blue (Sigma), iv) be injected into the tail vein (normal control group is injected with antigen and the pigment Evan's Blue mixed solution of same volume), antigen will react with the antibody that is attached to the mast cell and cause local allergic reaction, local vascular permeability raises, and pigment penetrates into tissue, and by measuring the content of local pigment after 30min, judges reaction intensity. Collect left and right ears dye and extract, specific wavelength measures the absorbance of Evan's blue, calculates its content (referring to Table 1, wherein the right ear Evan's Blue concentration of each group and the normal control group left ear all do not have significant differences) according to standard curve, assesses the pharmacodynamic effect of each tested drug in PCA animal model.

[0174] Table 1

[0175] The experimental results showed that compared with the normal control group, the model group mice had significantly increased ear weight on the modeling side (left side) and significantly increased Evan's Blue content in the ears. Compared with the model group, all three dose groups of Compound (I) significantly reduced Evan's Blue content in the model animals' ears, demonstrating significant efficacy. The low and medium dose groups showed a dose-response relationship, with the same dose being comparable to LOU-064. The low dose was comparable to prednisone and cetirizine. Therefore, Compound (I) has a good therapeutic effect on anti-DNP IgE-induced passive cutaneous allergic reactions in mice.

[0176] Example 2: Clinical trial study of compound (I) capsules

[0177] 1. Test method

[0178] This example recruited 96 healthy Chinese subjects aged 18-45 years as subjects. The trial included 8 dose groups, each with a total of 12 subjects, who were randomly divided into groups. 10 of them received compound (I) capsules (i.e., the experimental group) and 2 received placebo capsules (not containing compound (I) as the control group or placebo group). The compound (I) capsules in this example were prepared by filling the capsules with the ingredients containing compound (I); the difference between the placebo capsules and the compound (I) capsules was that they did not contain the compound (I) ingredient. The doses involved in this example are all the amounts of compound (I). Based on safety and exploratory factors, the human MRSD (maximum recommended starting dose) of the compound (I) capsules used in the example was set at 10 mg, and the human maximum recommended dose was set at 800 mg. A total of 8 dose groups were set up between the initial dose and the maximum dose (see Table 2 for the dose escalation plan for the clinical trial): 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg, and single-dose safety and tolerability tests were conducted in each group.

[0179] Subjects fasted for 10 hours before administration and took a single oral dose of Compound (I) capsules or placebo capsules at the prescribed dose on the morning of the test day. No water was allowed within 2 hours after administration and no food was allowed within 4 hours after administration. Blood sample collection: 3.0 ml of venous blood was collected before administration (within 45 minutes) and at 10 minutes, 20 minutes, 0.5 hours, 1 hour, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 ​​hours, and 72 hours after administration. Urine sample collection: Urine samples were collected before administration (within 2 hours) and at 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours, 12-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours after administration. Feces collection: Feces were collected before administration (within 3 days) and at 0-24h, 24-48h, and 48-72h after administration.

[0180] Table 2: Dose escalation schedule for a Phase I single-dose clinical trial of Compound (I) capsules

[0181] 2. Statistical analysis methods

[0182] 2.1 Statistical analysis of pharmacokinetics

[0183] Per-protocol population: All subjects who met the inclusion criteria, did not meet the exclusion criteria, had no major protocol deviations, and completed medication, pharmacokinetic and pharmacodynamic sampling, and safety assessments according to the protocol constituted the per-protocol population of this study.

[0184] The per-protocol set was used for analysis. WinNonlin version 6.4 was used to process the plasma concentration data of compound (I) capsules over time. The non-compartmental model was used to calculate the main pharmacokinetic parameters of each subject. The power function model was used to analyze the relationship between dose and C max , AUC 0-t linear relationship.

[0185] 2.2 Statistical analysis of pharmacodynamics

[0186] ELISA was used to detect the receptor occupancy of compound (I) in human peripheral blood mononuclear cell lysate. This analysis method is a relative quantitative determination of BTK in human peripheral blood mononuclear cells (PBMC) using ELISA.

[0187] PBMC lysate containing BTK was incubated with compound (I), with no compound (I) added as a control, and then incubated with biotinylated compound (I). The cells were then added to a streptavidin-coated plate. When compound (I) was co-incubated with the PBMC lysate, it bound to BTK, thereby preventing BTK from binding to the biotinylated compound (I). Since this complex was unable to bind to the plate, a response signal was not generated.

[0188] Rabbit anti-BTK primary antibody is incubated with the above samples and will bind to BTK. Tetramethylbenzidine (TMB) is the substrate for the HRP-coupled anti-rabbit secondary antibody. The reaction is terminated by sulfuric acid. After color development, the absorbance is measured at a wavelength of 450nm. 620nm can be used for background correction. The content of free BTK is proportional to the absorbance, which can be used to indirectly detect the content of BTK. Data processing is as follows:

[0189] Free BTK (%) = 100% × [(S 样本X -S 样品X+化合物(I) ) / (S 第1天给药前 -S 第1天给药前+化合物(I) )]

[0190] Note: S 样本X : Indicates the absorbance value of the sample X to be tested;

[0191] S 样品X+化合物(I) : represents the absorbance value of the sample X after adding compound (I) [10uM], which serves as the background reference of the sample;

[0192] S 第1天给药前 : represents the signal value of the sample before the first administration;

[0193] S 第1天给药前+化合物(I) : represents the absorbance value after adding compound (I) [10uM] to the sample before the first administration, which serves as the background reference of the sample.

[0194] BTK occupancy % = 100% - free BTK %.

[0195] Per-protocol analysis was performed. The Chi-Square test was used to analyze the differences in BTK target site occupancy between the different dose groups, and logistic regression was used to analyze the relationship between dose, blood concentration, and BTK target site occupancy.

[0196] 2.3 Safety and Tolerability Assessment and Statistical Analysis

[0197] The safety data set included all subjects who received at least one dose and had post-dose safety data. Safety evaluation indicators included adverse events / adverse reactions, laboratory tests, electrocardiograms, vital signs, physical examinations, thyroid ultrasound, upper abdominal CT, and chest X-rays. All subjects in the placebo group were combined into one group. A safety analysis set was used, with safety indicators primarily described using statistical methods. Comparisons were performed before and after treatment within each treatment group, between each dose group, and between the treatment group and the placebo group.

[0198] 3. Results Analysis

[0199] 3.1 Pharmacokinetics

[0200] After single-dose administration of compound (I) capsules to healthy subjects, the CL / F, Vz / F, and T values ​​of compound (I) capsules in eight dose groups were significantly different. 1 / 2 , MRT 0-t , MRT 0-∞ and T max The difference was statistically significant (p<0.05), while the difference in CLr was not statistically significant (p>0.05) (see Table 3 for details). In the dose range of 10mg to 800mg, the βC max =1.0740, within the range of 0.8 to 1.25. The slope of the linear equation βC max The 90% confidence interval of the results was 1.0247-1.1234, and some of them fell within the judgment interval of 0.9491-1.0509, indicating that within the dose range of 10 mg to 800 mg, the C max It has a linear pharmacokinetic trend (see Figure 1 and Table 4 for details). In addition, in the range of 10-100 mg (Figure 2 and Table 5) and 200-800 mg (Figure 3 and Table 6), AUC 0-t It shows a linear pharmacokinetic trend.

[0201] Table 3: Pharmacokinetic parameters of compound (I) after capsule administration

[0202] Note: Data are expressed as mean ± standard deviation.

[0203] C max represents the peak concentration; T max represents the peak time; λ z represents the terminal elimination rate constant; AUC represents the area under the plasma concentration-time curve, where AUC 0-t The area under the blood drug concentration-time curve from time zero to the last quantifiable blood sampling point, AUC 0-∞The area under the plasma drug concentration-time curve from time zero to infinite time, AUC _%Extrap The residual area percentage (AUC _%Extrap =[(AUC 0-∞ -AUC 0-t ) / AUC 0-∞ ]×100%). T 1 / 2 represents the terminal elimination half-life, V z / F represents the apparent volume of distribution in the terminal phase after non-intravenous administration, CL / F represents the apparent systemic clearance of the drug from plasma after oral administration, and MRT last It represents the average residence time from zero to the lowest detectable blood drug concentration. INF_obs represents the mean residence time extrapolated from zero to infinity, and CLr represents the renal clearance rate of the drug from plasma.

[0204] Table 4: C of Compound (I) capsules at doses of 10 to 800 mg after single administration max Linear evaluation results of the power function model with dose

[0205] Power function model formula: PK = α * dose β .

[0206] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.

[0207] Table 5: AUC of Compound (I) capsules at 10-100 mg doses after single administration to healthy subjects 0-t Linear evaluation results of the power function model with dose

[0208] Power function model formula: PK = α * dose β .

[0209] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θH =1.25.

[0210] Table 6: AUC of Compound (I) capsules at doses of 200 to 800 mg after a single dose in healthy subjects 0-t Linear evaluation results of the power function model with dose

[0211] Power function model formula: PK = α * dose β .

[0212] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.

[0213] 3.2 Pharmacodynamics

[0214] After a single 10 mg dose of Compound (I) capsules, the maximum BTK target occupancy was 58.93%. At single doses of 25 mg and above, the maximum BTK target occupancy approached 100% (see Figure 4 for details). The time to peak activity was 0.5-4 hours, and this time gradually decreased with increasing dose. In the placebo group, the BTK target occupancy remained between 20-30% for most of the time.

[0215] 3.3 Relationship between pharmacokinetics and pharmacodynamics

[0216] Based on the pharmacokinetic and pharmacodynamic data obtained for each dose, the quantitative relationship between pharmacokinetics and pharmacodynamics was analyzed.

[0217] The data fitting shows that at lower C max and AUC last Under these conditions, the BTK target occupancy rate can reach nearly 100% (see Figures 5-6 for details).

[0218] 3.4 Security

[0219] Twenty-nine of the 96 subjects experienced 44 adverse events (AEs), of which 1 was a pre-dose adverse event and the remaining 43 were treatment-related adverse events (TEAEs). In the Compound (I) group, 25 subjects (31.3%) experienced 35 TEAEs, while in the placebo group, 4 subjects (25%) experienced 8 TEAEs. All TEAEs were Grade 1, except for one Grade 2 AE, anemia, in the placebo group (see Table 7 for details).

[0220] In the trial group, except for two AEs (upper respiratory tract infection, eyelid surgery) that were treated with medication and one AE (upper respiratory tract infection) that was treated with a medical antipyretic patch, no intervention was taken for the remaining AEs and they resolved spontaneously to normal or baseline levels. With the exception of two nephrolithiasis AEs that were clearly unrelated to the trial drug and resolved without change, all other AEs resolved. Ten AEs occurring in nine subjects were judged to be possibly related to the trial drug and were adverse reactions. The incidence of adverse events was higher in the 50, 100, 200, and 400 mg dose groups, all at 50%, while no adverse events occurred in the 800 mg dose group. The incidence of AEs in the other dose groups ranged from 10-30%. There was no apparent dose-related adverse event rate. In the placebo group, except for one AE (anemia) that was treated with medication and one AE (dizziness) that was treated with oral glucose, no intervention was taken for the remaining AEs and they resolved spontaneously to normal levels. All AEs resolved. The incidence of adverse reactions was 12.5% ​​(2 / 16). No SAEs (serious adverse events) occurred in this trial, and no AEs leading to withdrawal from the trial occurred (see Tables 8 and 9 for details).

[0221] Table 7: Summary of adverse event incidence during the trial

[0222] aThe severity of adverse reactions was graded according to CTACE version 4.03.

[0223] Table 8: Systemic adverse events in subjects after administration

[0224] Note: Adverse events were coded according to MedDRA V23.0.

[0225] Table 9: Adverse reactions caused by treatment

[0226] Note: Adverse events were coded according to MedDRA V23.0.

[0227] In summary, this example studies the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral administration of Compound (I) capsules in healthy adult subjects. The test results show that within the range of a single dose of 10 to 800 mg, the T max 1.03-2.00h, T 1 / 2 0.847-8.67h, C max The AUC is 46.1-5060 ng / mL, which increases with the dose, showing a linear pharmacokinetic trend. 0-tThe BTK occupancy rate (CCR) ranged from 77.7 to 14,392 h*ng / m, increasing with dose within the 10mg-100mg and 200mg-800mg dose ranges, demonstrating a linear pharmacokinetic trend. CL / F was similar in the low-dose groups (10-50mg) and decreased with increasing dose. MRT was short, ranging from 1.53 to 4.25h, and slightly prolonged with increasing dose. The maximum BTK occupancy rate was 58.93% in the 10mg dose group and approached 100% in the 25mg and above dose groups. All AEs in the experimental groups were Grade 1 in severity, with only one Grade 2 AE occurring in the placebo group.

[0228] A Phase IIa clinical trial was designed to evaluate the efficacy and safety of compound (I) after 4 weeks of administration, with a primary efficacy analysis conducted in the fourth week. The Phase IIa clinical trial adopted a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of compound (I) in patients. The trial included patients who had been diagnosed with chronic spontaneous urticaria (CSU) at the time of randomization and met the following requirements: (1) itching and wheals had persisted for at least 6 weeks before screening, despite taking second-generation H1 antihistamines for CSU during this period; (2) the 7-day Urticaria Activity Score (UAS7) (range 0-42) was ≥16 points, the 7-day Wheal Severity Score (HSS7) (range 0-21) was ≥6 points, and the 7-day Itch Severity Score (ISS7) (range 0-21) was ≥6 points for 7 consecutive days (-8 to -2 days) before randomization; (3) the duration of CSU before screening was ≥6 months (defined as the onset of CSU confirmed by the investigator based on all available supportive records). After randomization, patients received compound (I) or placebo at a dose of 25 mg twice daily. Preliminary results were evaluated using the UAS7, 7-day pruritus severity score (ISS7), 7-day wheal severity score (HSS7), Dermatology Life Quality Index (DLQI), Urticaria Control Test (UCT), and Angioedema Activity Score (AAS7) scales to assess the improvement of patients' urticaria-related symptoms at week 4 or 5 after administration.

[0229] The Phase IIa trial will evaluate the compound (I)'s ability to improve urticaria-related symptoms in patients with chronic spontaneous urticaria, as well as its safety in patients.

[0230] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0231] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. Use of a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of a compound represented by formula (I) in the preparation of a medicament for treating and / or preventing immune system diseases; 2. Use of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, or pharmaceutically acceptable salts of the compound represented by formula (I) in the treatment and / or prevention of immune system diseases; 3. A compound of formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of a compound of formula (I) for use in treating and / or preventing immune system diseases; 4. The use according to claims 1 to 3, characterized in that The immune system disease includes autoimmune disease and / or skin allergy disease.

5. The use according to claims 1 to 3, characterized in that Such immune system disorders include rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

6. The use according to claims 1 to 3, characterized in that The effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 5 to 800 mg.

7. The use according to claims 1 to 3, characterized in that The effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 10 to 800 mg.

8. The use according to claims 1 to 3, characterized in that The effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 20 to 800 mg.

9. The use according to claims 1 to 3, characterized in that The effective dose of the compound represented by formula (I) or the stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts of the compound represented by formula (I) is about 25 to 800 mg.

10. A single-dose drug, characterized in that Contains about 1 to 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I) as an active ingredient, 11. The single-dose medicament according to claim 10, characterized in that The single-dose medicament is used for treating and / or preventing immune system diseases.

12. The single-dose medicament according to claim 11, characterized in that The immune system disease includes autoimmune disease and / or skin allergy disease.

13. The single-dose medicine according to any one of claims 11, characterized in that Such immune system disorders include rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

14. The single-dose medicament according to claim 10, characterized in that The active ingredient comprises about 5 to 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by formula (I).

15. The single-dose medicament according to claim 10, characterized in that The active ingredient comprises about 10 to 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by formula (I).

16. The single-dose medicament according to claim 10, characterized in that The active ingredient comprises about 20 to 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by formula (I).

17. The single-dose medicament according to claim 10, characterized in that The active ingredient comprises about 25 to 800 mg of the compound represented by formula (I) or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by formula (I).

18. A method for treating and / or preventing immune system diseases, characterized in that: include: administering to a subject a pharmaceutically acceptable dose of a compound of formula (I) or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt of the compound of formula (I) or a single dose of the drug according to any one of claims 10 to 17, 19. The method according to claim 18, characterized in that The immune system disease includes autoimmune disease and / or skin allergy disease.

20. The method according to claim 18, wherein Such immune system disorders include rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

Citation Information

Patent Citations

  • Compounds and preparing method and applications thereof

    CN104086551A

  • BTK inhibitors

    CN105837576A

  • Aminopyridazinone compounds as protein kinase inhibitors

    CN106573001A

  • Crystallization form of BTK inhibitor, and preparation method thereof

    CN106939002A

  • Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

    CN113795255A